SPR is a powerful, industry accepted ligand discovery technology that is orthogonal to NMR. We have shown that the combination of TINS screening with Biacore™ fragment characterization forms a powerful workflow for drug discovery (Kobayashi, J. Biomol. Screen., 2010). Our integrated platform of TINS and SPR (Biacore™ T200 & 4000) allows us to further leverage our expertise in protein immobilization for the benefit of our customers.
The sensorgrams above show the titrations of three Hsp90 fragment hits that were identified by TINS screening. The KD determined by Biacore™, varying from double digit µM to a few hundred µM, is in good correspondence with the values determined via protein observed NMR, as depicted in the figure below.